SCHEMBL10154589

SCHEMBL10154589

CCNC(=O)N[C@@H](C)c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CASR P41180 1/20 0.69
EPHX2 P34913 4/20 0.63
HSD17B10 Q99714 2/20 0.62
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
POLB P06746 2/20 0.54
GPR139 Q6DWJ6 1/20 0.54
CTDSP1 Q9GZU7 1/20 0.53
MAPT P10636 1/20 0.53
EPHX1 P07099 2/20 0.53
LMNA P02545 2/20 0.53
OPRM1 P35372 1/20 0.52
OPRD1 P41143 1/20 0.52
OPRK1 P41145 1/20 0.52
MAPK1 P28482 1/20 0.51
MTOR P42345 1/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8715644 0.85 HSD17B10 (0.75) CASREPHX2HSD17B10MEN1KMT2A
SCHEMBL924286 0.85 HSD17B10 (0.75) CASREPHX2HSD17B10MEN1KMT2A
SCHEMBL8715641 0.85 HSD17B10 (0.75) CASREPHX2HSD17B10MEN1KMT2A
SCHEMBL15093717 0.85 HSD17B10 (0.75) CASREPHX2HSD17B10MEN1KMT2A
SCHEMBL29753182 0.84 EPHX2 (0.80) CASREPHX2HSD17B10MEN1KMT2A
SCHEMBL13480537 0.84 NPSR1 (0.58) CASREPHX2MEN1KMT2APOLB
SCHEMBL12678184 0.83 EPHX2 (0.74) CASREPHX2HSD17B10MEN1KMT2A
SCHEMBL6436940 0.83 EPHX2 (0.68) CASREPHX2HSD17B10MEN1KMT2A
SCHEMBL15263405 0.83 EPHX2 (0.78) CASREPHX2HSD17B10MEN1KMT2A
SCHEMBL10125347 0.83 OPRM1 (0.54) CASREPHX2HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9765087-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2017-09-19 US disclosed
US-20170114046-A1 NOVEL BENZIMIDAZOLE DERIVATIVES ENANTA PHARM INC (US) 2017-04-27 US disclosed
EP-2400846-B1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARM INC (US) 2016-10-05 EP disclosed
US-9000020-B2 Linked dibenzimidazole antivirals ENANTA PHARMACEUTICALS, INC. (US) 2015-04-07 US disclosed
US-20140341851-A1 NOVEL BENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. (US) 2014-11-20 US disclosed
US-20140193363-A1 NOVEL BENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. (US) 2014-07-10 US disclosed
US-8673954-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2014-03-18 US disclosed
US-8637561-B2 Linked diimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2014-01-28 US disclosed
US-20130295049-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS ENANTA PHARMACEUTICALS, INC (US) 2013-11-07 US disclosed
US-8507522-B2 Hepatitis C virus inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-8420686-B2 Linked diimidazole antivirals ENANTA PHARMACEUTICALS, INC. (US) 2013-04-16 US disclosed
US-8101643-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-20100266543-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS ENANTA PHARMACEUTICALS, INC. 2010-10-21 US disclosed
US-20100233122-A1 NOVEL BENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114046-A1 NOVEL BENZIMIDAZOLE DERIVATIVES EIF2AK2, ZC3HAV1, HAVCR2 CASR 4817/4885EPHX2 3365/4885HSD17B10 906/4885
US-20100233122-A1 NOVEL BENZIMIDAZOLE DERIVATIVES EIF2AK2, ZC3HAV1, HAVCR2 CASR 4817/4885EPHX2 3365/4885HSD17B10 906/4885
US-20100266543-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS EIF2AK2, ZC3HAV1, NSUN2 CASR 4854/4885EPHX2 1694/4885HSD17B10 1019/4885
US-20140193363-A1 NOVEL BENZIMIDAZOLE DERIVATIVES EIF2AK2, ZC3HAV1, HAVCR2 CASR 4817/4885EPHX2 3365/4885HSD17B10 906/4885
US-20130295049-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS EIF2AK2, ZC3HAV1, NSUN2 CASR 4854/4885EPHX2 1694/4885HSD17B10 1019/4885
US-20140341851-A1 NOVEL BENZIMIDAZOLE DERIVATIVES EIF2AK2, ZC3HAV1, HAVCR2 CASR 4817/4885EPHX2 3365/4885HSD17B10 906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.